Twist Bioscience announced the expansion of its high-throughput antibody portfolio with the launch of a CHO cell line for Twist Express Antibodies. Twist also offers HEK293 expression Twist Express Antibodies. “With the majority of biotherapeutic drugs manufactured in CHO cell lines, expressing small-scale therapeutic antibody candidates in CHO for screening has become a vital first step to ensure successful downstream scale-up. We now provide a comprehensive portfolio of antibody production to further serve the biopharma market by offering both HEK293 with reduced turnaround times enabled by our Express Genes as well as the newly launched CHO cell line for Twist Express Antibodies,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By taking on the process of antibody development from sequence to protein, we meet the needs of therapeutic developers who currently make their own antibodies, a costly bottleneck in the discovery pipeline, providing them with a cost-effective, customizable, and scalable offering to support their research.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $60 from $45 at Barclays
- Twist Bioscience price target raised to $65 from $55 at TD Cowen
- Twist publishes study detailing the discovery of TB206-001 targeting A2AR
- Twist extends rally as Wall Street sees opportunity amid GenScript scrutiny
- Twist Bioscience initiated with a Buy at Guggenheim (yesterday)
Questions or Comments about the article? Write to editor@tipranks.com